Monte Rosa Therapeutics Inc. (Nasdaq: GLUE) Stock Rockets After License Agreement with Novartis
One stock that is highly likely to be on the radars of investors this morning is that of Monte Rosa Therapeutics Inc. (Nasdaq: GLUE), which delivered staggering gains of 94% on Monday. Let’s take a look at the development that led to such gains. Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders Yesterday, the company garnered considerable attention from…